CD56 detection method of endometrial tissue and application of CD56 detection method

Abstract

The invention relates to the technical field of biomedical engineering, in particular to an endometrial tissue CD56 detection method and application thereof, and the endometrial tissue CD56 detection method comprises the following steps: S1, obtaining an endometrial tissue sample by adopting a non-invasive or minimally invasive method; s2, carrying out standardization treatment on the collected endometrial tissue sample; s3, performing immunohistochemical staining; s4, performing digital analysis; and S5, judging a result. According to the research, the endometrial tissue is obtained under the endometrial sampler, the expression level of CD56 in the endometrial tissue is detected through immunohistochemistry, and an RSA patient with the too high CD56 level is subjected to immunoregulation treatment, so that the pregnancy outcome is improved, and compared with traditional diagnostic curettage, the endometrial curettage has the advantage of being small in endometrial damage, and the clinical application prospect is broad. Compared with a hysteroscope endometrial biopsy operation, the method has the advantages of being convenient to operate and low in cost.

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical engineering, and in particular to a method for detecting CD56 in endometrial tissue and an application thereof. Background Art

[0002] The incidence of recurrent spontaneous abortion (RSA) in women of childbearing age is about 1% to 5%, which has caused a great double blow to the patient's physical health and emotional state. About 50% of RSA patients are cases of unexplained spontaneous abortion (URSA), that is, cases where the cause of abortion cannot be determined. Studies in reproductive immunology have shown that URSA is closely related to immune imbalance at the maternal-fetal interface. The immune microenvironment at the maternal-fetal interface is crucial to the maintenance of pregnancy, and abnormal immune balance may lead to miscarriage. The immune microenvironment at the maternal-fetal interface involves complex interactions between immune cells such as uterine decidual stromal cells, trophoblasts, natural killer (NK) cells, T cells, and macrophages. These mechanisms have been a research hotspot in recent years.

[0003] NK cells are an important component of peripheral circulating lymphocytes, accounting for 10% to 15%. In early pregnancy, the proportion of NK cells in the decidua is as high as 70%, and they play an important role in immune regulation. NK cells exert immunoregulatory effects on pregnancy by recognizing target cells or secreting cytokines. Studies have found that there is a close relationship between abnormally high expression of NK cells and RSA. Summary of the invention

[0004] In view of the above-mentioned shortcomings of the prior art, the present invention provides a CD56 detection method for endometrial tissue and its application, which can effectively solve the problems of inconvenience and high cost of recurrent miscarriage detection in the prior art.

[0005] To achieve the above objectives, the present invention is implemented through the following technical solutions:

[0006] The present invention provides a method for detecting CD56 in endometrial tissue, comprising the following steps:

[0007] S1: Non-invasive or minimally invasive methods are used to obtain endometrial tissue samples;

[0008] S2: Standardize the processing of collected endometrial tissue samples;

[0009] S3: immunohistochemical staining;

[0010] S4: Digital analysis;

[0011] S5: Result determination.

[0012] Furthermore, sampling is performed using techniques such as an endometrial cell collector, hysteroscopy or endometrial biopsy.

[0013] Furthermore, the standardized treatment includes the steps of fixation, dehydration, and embedding. The samples are fixed in a 10% formalin solution, embedded in paraffin after dehydration, and prepared into 4-5 micron thick tissue sections.

[0014] Furthermore, specific anti-CD56 antibodies were used to perform immunohistochemical staining on tissue sections, and high-quality commercial anti-CD56 primary antibodies and optimized secondary antibody labeling methods were selected to ensure the specificity and sensitivity of staining.

[0015] Furthermore, a digital pathology scanning system was used to perform high-resolution scanning on the stained tissue sections to obtain high-definition images, and image analysis software was used to quantitatively analyze the expression of CD56 to calculate the number of CD56-positive cells and their distribution characteristics in the tissue.

[0016] Furthermore, the immune status and pathological changes of the endometrium were evaluated based on the expression level and distribution characteristics of CD56. The increased positive expression of CD56 indicated that the endometrium had pathological conditions such as inflammatory response, neovascularization or abnormal proliferation, which was associated with the occurrence of RSA.

[0017] The CD56 detection method of endometrial tissue is used in immunomodulatory treatment of RSA patients.

[0018] Compared with the known prior art, the technical solution provided by the present invention has the following beneficial effects:

[0019] In this study, endometrial tissue was obtained under an endometrial sampler, and the expression level of CD56 in the endometrial tissue was detected by immunohistochemistry. Immunomodulatory treatment was performed on RSA patients with excessively high CD56 levels, thereby improving pregnancy outcomes. Compared with traditional diagnostic curettage, this method has the advantage of less damage to the endometrium, and compared with hysteroscopic endometrial biopsy, this method has the advantages of easy operation and low cost. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0021] Figure 1 Flow chart of the method of the present invention. DETAILED DESCRIPTION

[0022] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0023] The present invention will be further described below in conjunction with the embodiments.

[0024] Embodiment: A method for detecting CD56 in endometrial tissue and its application, comprising the following steps:

[0025] S1: Non-invasive or minimally invasive methods are used to obtain endometrial tissue samples;

[0026] Sampling by endometrial cell harvester, hysteroscopy or endometrial biopsy

[0027] S2: Standardize the processing of collected endometrial tissue samples;

[0028] The standardized treatment includes fixation, dehydration, and embedding steps. The samples are fixed in 10% formalin solution, dehydrated, embedded in paraffin, and prepared into 4-5 micron thick tissue sections.

[0029] S3: immunohistochemical staining;

[0030] Use specific anti-CD56 antibody to perform immunohistochemical staining on tissue sections. Select high-quality commercial anti-CD56 primary antibody and optimized secondary antibody labeling method to ensure the specificity and sensitivity of staining.

[0031] S4: Digital analysis;

[0032] The stained tissue sections were scanned at high resolution using a digital pathology scanning system to obtain high-definition images. Image analysis software was used to quantitatively analyze the expression of CD56 and calculate the number of CD56-positive cells and their distribution characteristics in the tissue.

[0033] S5: Result determination.

[0034] The immune status and pathological changes of the endometrium were evaluated based on the expression level and distribution characteristics of CD56. The increased positive expression of CD56 indicated that the endometrium had pathological conditions such as inflammatory response, neovascularization or abnormal proliferation, which was associated with the occurrence of RSA.

[0035] The CD56 detection method of endometrial tissue is applied in immunomodulatory treatment of RSA patients.

[0036] Endometritis Diagnosis:

[0037] By detecting the expression level of CD56 in endometrial tissue, the diagnosis of endometritis can be assisted. A significant increase in the positive expression of CD56 may indicate the presence of an inflammatory response in the endometrium, providing a strong basis for the diagnosis of inflammation.

[0038] Endometrial Dysplasia Screening:

[0039] For patients suspected of endometrial hyperplasia, CD56 testing is used to assess their risk. High expression levels of CD56 may indicate the presence of abnormal hyperplasia, which helps to identify it early and take appropriate measures.

[0040] Early diagnosis of endometrial cancer:

[0041] Combined with other clinical information, CD56 detection can be used for early screening and diagnosis of endometrial cancer. Specific changes in CD56 expression in malignant cells can serve as an important marker for early cancer screening.

[0042] Hormone Replacement Therapy Monitoring:

[0043] For postmenopausal women receiving hormone replacement therapy, monitoring the expression changes of CD56 in endometrial tissue can be used to evaluate the therapeutic effect and potential side effects (such as abnormal uterine bleeding). CD56 detection can be used as an important tool for evaluating the therapeutic effect.

[0044] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements will not cause the essence of the corresponding technical solutions to deviate from the protection scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for detecting CD56 in endometrial tissue, comprising the following steps: S1: Non-invasive or minimally invasive methods are used to obtain endometrial tissue samples; S2: Standardize the processing of collected endometrial tissue samples; S3: immunohistochemical staining; S4: Digital analysis; S5: Result determination.

2. The method for detecting CD56 in endometrial tissue according to claim 1, characterized in that: Sampling is done through techniques such as an endometrial cell collector, hysteroscopy, or endometrial biopsy.

3. The method for detecting CD56 in endometrial tissue according to claim 1, characterized in that: The standardized treatment includes the steps of fixation, dehydration and embedding. The sample is fixed in a 10% formalin solution, embedded in paraffin after dehydration, and prepared into 4-5 micron thick tissue sections.

4. The method for detecting CD56 in endometrial tissue according to claim 1, characterized in that: Use specific anti-CD56 antibody to perform immunohistochemical staining on tissue sections. Select high-quality commercial anti-CD56 primary antibody and optimized secondary antibody labeling method to ensure the specificity and sensitivity of staining.

5. The method for detecting CD56 in endometrial tissue according to claim 1, characterized in that: The stained tissue sections were scanned at high resolution using a digital pathology scanning system to obtain high-definition images. Image analysis software was used to quantitatively analyze the expression of CD56 and calculate the number of CD56-positive cells and their distribution characteristics in the tissue.

6. The method for detecting CD56 in endometrial tissue according to claim 1, characterized in that: The immune status and pathological changes of the endometrium were evaluated based on the expression level and distribution characteristics of CD56. The increased positive expression of CD56 indicated that the endometrium had pathological conditions such as inflammatory response, neovascularization or abnormal proliferation, which was associated with the occurrence of RSA.

7. Use of the CD56 detection method for endometrial tissue according to claim 1 in immunomodulatory treatment of RSA patients.

Images